Zobrazeno 1 - 10
of 892
pro vyhledávání: '"Michael, Untch"'
Autor:
Philipp Ziegler, Andreas D. Hartkopf, Markus Wallwiener, Lothar Häberle, Hans-Christian Kolberg, Peyman Hadji, Hans Tesch, Johannes Ettl, Diana Lüftner, Volkmar Müller, Laura L. Michel, Erik Belleville, Pauline Wimberger, Carsten Hielscher, Hanna Huebner, Sabrina Uhrig, Lena A. Wurmthaler, Carolin C. Hack, Christoph Mundhenke, Christian Kurbacher, Peter A. Fasching, Rachel Wuerstlein, Michael Untch, Wolfgang Janni, Florin-Andrei Taran, Michael P. Lux, Diethelm Wallwiener, Sara Y. Brucker, Tanja N. Fehm, Andreas Schneeweiss, Chloë Goossens
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-12 (2024)
Abstract Background Although adequate physical activity has been shown to be beneficial in early breast cancer, evidence in metastatic breast cancer is sparse and contradictory, which could be related to distinct effects of physical activity on the d
Externí odkaz:
https://doaj.org/article/f6addaf5728b4463afe3407a59ff7008
Autor:
Bruno Valentin Sinn, Katharina Sychra, Michael Untch, Thomas Karn, Marion van Mackelenbergh, Jens Huober, Wolfgang Schmitt, Frederik Marmé, Christian Schem, Christine Solbach, Elmar Stickeler, Hans Tesch, Peter A. Fasching, Andreas Schneeweiss, Volkmar Müller, Johannes Holtschmidt, Valentina Nekljudova, Sibylle Loibl, Carsten Denkert
Publikováno v:
Breast Cancer Research, Vol 26, Iss 1, Pp 1-11 (2024)
Abstract Background Patients with pathologic complete response (pCR) to neoadjuvant chemotherapy for invasive breast cancer (BC) have better outcomes, potentially warranting less extensive surgical and systemic treatments. Early prediction of treatme
Externí odkaz:
https://doaj.org/article/7254adee1eef456f91cca8c6f84490e2
Autor:
Volker Möbus, Hans-Joachim Lück, Ekkehart Ladda, Peter Klare, Knut Engels, Marcus Schmidt, Andreas Schneeweiss, Eva-Maria Grischke, Grischa Wachsmann, Helmut Forstbauer, Michael Untch, Frederik Marmé, Jens-Uwe Blohmer, Christian Jackisch, Jens Huober, Elmar Stickeler, Mattea Reinisch, Theresa Link, Bruno Sinn, Wolfgang Janni, Carsten Denkert, Sabine Seiler, Christine Solbach, Sabine Schmatloch, Julia Rey, Sibylle Loibl
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-10 (2024)
Abstract GAIN-2 trial evaluated the optimal intense dose-dense (idd) strategy for high-risk early breast cancer. This study reports the secondary endpoints pathological complete response (pCR) and overall survival (OS). Patients (n = 2887) were rando
Externí odkaz:
https://doaj.org/article/b93eb5cc3e364be681372848cc75b63c
Autor:
Peter A. Fasching, Chunling Hu, Steven N. Hart, Matthias Ruebner, Eric C. Polley, Rohan D. Gnanaolivu, Andreas D. Hartkopf, Hanna Huebner, Wolfgang Janni, Peyman Hadji, Hans Tesch, Sabrina Uhrig, Johannes Ettl, Michael P. Lux, Diana Lüftner, Markus Wallwiener, Lena A. Wurmthaler, Chloë Goossens, Volkmar Müller, Matthias W. Beckmann, Alexander Hein, Daniel Anetsberger, Erik Belleville, Pauline Wimberger, Michael Untch, Arif B. Ekici, Hans-Christian Kolberg, Arndt Hartmann, Florin-Andrei Taran, Tanja N. Fehm, Diethelm Wallwiener, Sara Y. Brucker, Andreas Schneeweiss, Lothar Häberle, Fergus J. Couch
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-7 (2024)
Abstract Germline mutations in BRCA1 and BRCA2 (gBRCA1/2) are required for a PARP inhibitor therapy in patients with HER2-negative (HER2−) advanced breast cancer (aBC). However, little is known about the prognostic impact of gBRCA1/2 mutations in a
Externí odkaz:
https://doaj.org/article/7fc65e7d8ec9445caafcbb4945b9c522
Autor:
Chiara Massa, Thomas Karn, Karsten Weber, Andreas Schneeweiss, Claus Hanusch, Jens Uwe Blohmer, Dirk‐Michael Zahm, Christian Jackisch, Marion van Mackelenbergh, Jörg Thomalla, Frederik Marmé, Jens Huober, Volkmar Müller, Christian Schem, Anja Müller, Elmar Stickeler, Katharina Biehl, Peter A. Fasching, Michael Untch, Sibylle Loibl, Carsten Denkert, Barbara Seliger
Publikováno v:
Clinical and Translational Medicine, Vol 14, Iss 4, Pp n/a-n/a (2024)
Externí odkaz:
https://doaj.org/article/f921f7466a0a4b568dfafa8ea0d35cf6
Autor:
David Krug, Valentina Vladimirova, Michael Untch, Thorsten Kühn, Andreas Schneeweiss, Carsten Denkert, Beyhan Ataseven, Christine Solbach, Bernd Gerber, Hans Tesch, Michael Golatta, Sabine Seiler, Jörg Heil, Valentina Nekljudova, Johannes Holtschmidt, Sibylle Loibl
Publikováno v:
Breast, Vol 74, Iss , Pp 103701- (2024)
Background: Neoadjuvant chemotherapy (NACT) is routinely used for patients with triple-negative breast cancer (TNBC). Upfront breast-conserving therapy (BCT) consisting of breast-conserving surgery (BCS) and adjuvant radiotherapy (RT) has been shown
Externí odkaz:
https://doaj.org/article/8d2a63a4c8bd4f918241d9bea3fb337a
Autor:
Jens Huober, Marion van Mackelenbergh, Andreas Schneeweiss, Fenja Seither, Jens-Uwe Blohmer, Carsten Denkert, Hans Tesch, Claus Hanusch, Christoph Salat, Kerstin Rhiem, Christine Solbach, Peter A. Fasching, Christian Jackisch, Mattea Reinisch, Bianca Lederer, Keyur Mehta, Theresa Link, Valentina Nekljudova, Sibylle Loibl, Michael Untch
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-12 (2023)
Abstract This retrospective pooled analysis aims to identify factors predicting relapse despite a pathologic complete response (pCR) in patients with breast cancer (BC). 2066 patients with a pCR from five neoadjuvant GBG/AGO-B trials fulfill the incl
Externí odkaz:
https://doaj.org/article/1894262e05954747a7b2989d697dd085
Autor:
Mattea Reinisch, Michael Untch, Rolf Mahlberg, Toralf Reimer, Thomas Hitschold, Frederik Marmé, Mustafa Aydogdu, Sabine Schmatloch, Hans-Joachim Lück, Marcus Schmidt, Ekkehart Ladda, Bruno Valentin Sinn, Peter Klare, Wolfgang Janni, Christian Jackisch, Carsten Denkert, Sabine Seiler, Thomas Göhler, Laura Michel, Nicole Burchardi, Elmar Stickeler, Julia Rey, Nicole Klutinus, Volker Möbus, Sibylle Loibl
Publikováno v:
Breast, Vol 66, Iss , Pp 110-117 (2022)
Background: Trastuzumab given intravenously in combination with chemotherapy is standard of care for patients with early HER2-positive breast cancer (BC). Different randomised studies have shown equivalent efficacy of a subcutaneous injection into th
Externí odkaz:
https://doaj.org/article/916f38f5626a45b9afb718606995934e
Autor:
Sibylle Loibl, Chiun-Sheng Huang, Max S. Mano, Eleftherios P. Mamounas, Charles E. Geyer, Michael Untch, Jean-Christophe Thery, Ingo Schwaner, Steven Limentani, Niklas Loman, Kristina Lübbe, Jenny C. Chang, Thomas Hatschek, David Tesarowski, Chunyan Song, Sanne Lysbet de Haas, Thomas Boulet, Chiara Lambertini, Norman Wolmark
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-6 (2022)
Abstract Following chemotherapy and human epidermal growth factor 2 (HER2)-targeted neoadjuvant therapy for HER2-positive early breast cancer, residual invasive breast cancer at surgery may be HER2-negative on retesting in some patients. We evaluated
Externí odkaz:
https://doaj.org/article/c268c669d03547e1b3867ec85f83f413
Autor:
Dennis J. Slamon, Peter A. Fasching, Sara Hurvitz, Stephen Chia, John Crown, Miguel Martín, Carlos H. Barrios, Aditya Bardia, Seock-Ah Im, Denise A. Yardley, Michael Untch, Chiun-Sheng Huang, Daniil Stroyakovskiy, Binghe Xu, Rebecca L. Moroose, Sherene Loi, Frances Visco, Valerie Bee-Munteanu, Karen Afenjar, Rodrigo Fresco, Tetiana Taran, Arunava Chakravartty, Juan Pablo Zarate, Agnes Lteif, Gabriel N. Hortobagyi
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Background: Ribociclib has demonstrated a statistically significant overall survival benefit in pre- and postmenopausal patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer. Ne
Externí odkaz:
https://doaj.org/article/73d02bee3f9e4dc6a76bef48c3ed8ce0